Movatterモバイル変換


[0]ホーム

URL:


GB2314840A - Oxidized oligosaccharides - Google Patents

Oxidized oligosaccharides
Download PDF

Info

Publication number
GB2314840A
GB2314840AGB9613683AGB9613683AGB2314840AGB 2314840 AGB2314840 AGB 2314840AGB 9613683 AGB9613683 AGB 9613683AGB 9613683 AGB9613683 AGB 9613683AGB 2314840 AGB2314840 AGB 2314840A
Authority
GB
United Kingdom
Prior art keywords
oxidized
oligosaccharide
composition according
solution
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9613683A
Other versions
GB2314840B (en
GB9613683D0 (en
Inventor
Peter John Doyle
Lowell Saferstein
Elaine Lorimer
Paul W Watt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Johnson and Johnson Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Medical IncfiledCriticalJohnson and Johnson Medical Inc
Priority to GB9613683ApriorityCriticalpatent/GB2314840B/en
Publication of GB9613683D0publicationCriticalpatent/GB9613683D0/en
Priority to CZ19984274Aprioritypatent/CZ294839B6/en
Priority to DE69702911Tprioritypatent/DE69702911T2/en
Priority to PCT/GB1997/001726prioritypatent/WO1998000446A1/en
Priority to PT97928373Tprioritypatent/PT907664E/en
Priority to KR1019980710708Aprioritypatent/KR20000022286A/en
Priority to EP97928373Aprioritypatent/EP0907664B1/en
Priority to BR9710003-0Aprioritypatent/BR9710003A/en
Priority to PL97330825Aprioritypatent/PL189194B1/en
Priority to JP50391398Aprioritypatent/JP4302187B2/en
Priority to AT97928373Tprioritypatent/ATE195742T1/en
Priority to AU32693/97Aprioritypatent/AU725296B2/en
Priority to HU9903404Aprioritypatent/HUP9903404A3/en
Priority to ES97928373Tprioritypatent/ES2148991T3/en
Priority to CA002258849Aprioritypatent/CA2258849C/en
Publication of GB2314840ApublicationCriticalpatent/GB2314840A/en
Application grantedgrantedCritical
Publication of GB2314840BpublicationCriticalpatent/GB2314840B/en
Priority to GR20000402542Tprioritypatent/GR3034853T3/en
Priority to JP2008314228Aprioritypatent/JP5208707B2/en
Anticipated expirationlegal-statusCritical
Revokedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The invention provides oligosaccharides having molecular weights in the range 1000 to 50,000 and obtained' by partial hydrolysis of oxidized polysaccharides such as oxidized regenerated cellulose (ORC). The oligosaccharides are useful as or in wound dressings, and for binding peptides or proteins.

Description

OXIDIZED OLIGOSACCEARIDES This invention relates to oxidized oligosaccharides such as oligosaccharides of oxidized regenerated cellulose (ORC). The invention also relates to the use of oxidized oligosaccharides in wound dressings and other medical and pharmaceutical applications, and to methods for preparing oxidized oligosaccharides.
ORC has long been manufactured and used medically to achieve haemostasis, and as a barrier material to prevent adhesions following surgery. A key feature of ORC is that it is absorbable when implanted in the body, whereas cellulose is not. ORC is resorbed by hydrolytic cleavage of the polymer to yield small oligosaccharides which are metabolized and eliminated from the body. Oxidation of cellulose to yield 10 to 21% carboxyl groups by weight of the cellulose allows substantially complete absorption of the material within two to three weeks following implantation.
ORC is manufactured by exposure of cellulose to an oxidizing agent such as dinitrogen tetroxide, as described in US-A-3122479. The physical form of cellulosic material is not critical. For example, the cellulosic film, paper, sponge and cloth may all be oxidized to yield ORC. However, the commercially preferred material is a woven or knitted fabric. ORC in the form of a knitted fabric is available under the Trade Mark SURGICEL for use as an absorbable haemostat, and ORC is also available under the Trade MarkINTERCEED for use as an adhesion barrier.
Polysaccharides other than cellulose may also be oxidized to yield medically useful haemostatic materials.
Such other polysaccharides include microbial polysaccharides such as dextran, gellan gum and xanthan gum; polysaccharides derived from plants, for example agar, starch, kon3ac, carrageenan, guar gum, inulin and pectin; and polysaccharide derivatives such as carboxymethyl cellulose, methylhydroxypropyl cellulose, cellulose acetate, methyl cellulose, and ethyl cellulose.
It has been proposed to combine ORC with other materials for use as wound dressings. For example, US-A2517772 (Doub et al ) discloses dressings formed from ORC impregnated with thrombin. However, ORC is significantly acidic. The surface pH of a fully water-saturated piece ofORC fabric may be as low as 1.7. Many proteinaceous agents, such as thrombin, are highly acid-sensitive, and are inactivated immediately on contact with such a matrix.
Accordingly, Doub et al teach that ORC should be neutralized prior to impregnation with thrombin. Calcium acetate, sodium bicarbonate, ammonia and alcoholic ethylamine are given as examples of suitable neutralizing agents, but Doub et al warn that ORC should not be neutralized to such a degree that it loses its fibrous nature when placed in water because of solution or gelling and disintegration.
EP-A-0437095 discloses that the use of aqueous solutions of sodium bicarbonate to neutralize ORC cloth results in a cloth which is partially gelled, distorted from its original size and very weak with little integrity. The tensile strength of the cloth is said to be too low for practical use such as, for example, a haemostat. Similar results are said to be obtained with the use of strongly basic aqueous sodium hydroxide and ammonium hydroxide solutions. EP-A-0437095 accordingly teaches a process for preparing a storage stable, non-irritating and therapeutic neutralized oxidized cellulose product comprising the steps of contacting an acid oxidized cellulose material with an alcohol and water solution of a slightly basic chloride-free salt of a weak acid to elevate the pH of the cellulose material to between 5 and 8; washing the elevated pH cellulose material with alcohol to remove excess salt and water; and drying the cellulose material to remove alcohol.
It has now been found that ORC and other oxidized polysaccharides can be partially hydrolysed under mild alkaline conditions to yield oligosaccharides which have a number of medically useful properties.
Accordingly, the present invention provides an oxidized oligosaccharide composition having an average molecular weight in the range 1000 to 50000 daltons.
In particular, the oxidized polysaccharides of the present invention bind therapeutically useful agents, and such bound agents can then be released in high yield. The oxidized oligosaccharides of the present invention can therefore be used in pharmaceutical compositions, for example in wound dressings, to deliver such agents to a wound site. The therapeutically useful agents which are bound by oxidized oligosaccharides include pharmaceutically active peptides and proteins, preferably growth factors such as PDGF AB, PDGF BB, TGF-Pl, TGF-P2, TGF-P3, basic FGF, acidic FGF and possibly EGF and TGF-a.
Without wishing to be bound by any theory, it is thought that the anionic carboxylate groups on the oxidized oligosaccharides complex to cationic amine groups on the peptides and proteins. Complexation to therapeutically active agents having anionic groups can also readily be achieved, for example, by use of polyvalent metal ions such as Ca2 or Zn2+ as ionic cross-linking agents.
A further advantage of the oxidized oligosaccharides of the present invention is that they may be intimately combined with other materials such as proteins and other polysaccharides (with or without chemical cross-linking) to form compositions having novel properties. For example, oxidized oligosaccharides may be combined with hyaluronic acid, chitosan, or an alginate (particularly sodium alginate, calcium alginate or a mixed sodium/calcium alginate) to form novel haemostatic compositions.
Alternatively, composites of oxidized oligosaccharides with other oligosaccharides, polysaccharides or proteins may be used as controlled release matrices for a variety of therapeutic agents such as antiseptics, antibiotics, protein growth factors, anti-inflammatories, analgesics, proteinase inhibitors such as aprotinin or the hydroxamic acids. The oxidized oligosaccharides of the present invention may be combined with a desired therapeutic agent while in solution (the therapeutic agent being either in solution in suspension), and the oligosaccharide may be then be removed from solution by suitable means, to yield a material in which the therapeutic agent is substantially uniformly distributed. Alternatively, the solvent may be removed, e.g. by freeze-drying.
Oxidized oligosaccharides may also be cross-linked so as to allow the formation of three-dimensional structures.
For example, oxidized oligosaccharides can be dissolved in water to which a very low concentration of pepsinsolubilized collagen is added. If carbodiimide is then added as a cross-linker, the collagen acts as a bridging group between the oligosaccharides, such that a threedimensional structure can be obtained by freeze drying.
The oxidized oligosaccharides of the present invention preferably have a molecular weight of at least 1000 daltons, and generally less than 100000. Most usually, the molecular weight will be less than 5000 to 30000 daltons. (It will be understood that the oxidized oligosaccharides of the present invention will generally form a mixed population of different sized molecules. Accordingly, references herein to oxidized oligosaccharides having a particular molecular weight range, and more preferably at least 90% by weight, of the molecules fall within the specified range.)In one embodiment, oligosaccharides according to the invention are derived from insoluble oxidized polysaccharides and are of such a molecular weight that they are soluble at neutral and alkaline pH, but insoluble at acid pH. Such oligosaccharides can be readily recovered from solution merely by reducing the pH, so causing them to precipitate. Alternatively, however, oxidized oligosaccharides can be recovered from solution by transferring them to a solution which does not contain any other non-volatile components, and then evaporating the solvent. For example, oxidized oligosaccharides can be isolated using an ion exchange solid phase extraction column (such as a phenyl boronic acid solid phase column, previously activated with methanol and equilibrated with dilute acetic acid), and then eluted with dilute (e.g. 0.lM) ammonium hydroxide solution.
Preferably, the oxidized oligosaccharides of the present invention have a carboxyl content of from 5 to 25% by weight, and more preferably from 8 to 14% by weight. The carboxyl content of the oligosaccharides is determined as follows:A sample of oxidized oligosaccharide (approximately 0.2g) is dissolved in 0.5M sodium hydroxide (5ml) and a couple of drops of 0.1% phenolphthalein indicator solution are added. The excess sodium hydroxide is back-titrated with 0.1M HCl to the phenolphthalein end point (red to clear). A blank value is determined by titrating 5ml 0.1M sodium hydroxide with 0.1M HCl. The value for carboxyl content is calculated using the equation:C = 4.5 x (B-S) x MWwherein:C = percent carboxyl contentB = volume of standard HCl to titrate blank (ml)S = volume of standard HCl to titrate sample (ml)M = morality of standard HClW = dry weight of sample (g) (4.5 = milliequivalent weight of carboxyl x 100)The present invention also provides a method of preparing an oxidized oligosaccharide, comprising treating an oxidized polysaccharide having a molecular weight of at least 50000 (more usually at least 100000, e.g. more than 30000) with an aqueous alkaline solution at a temperature and for a period of time sufficient to result in partial hydrolysis of said polysaccharide, and then recovering the resulting oxidized oligosaccharide from solution, e.g. by adjusting the pH to 7 or less. The alkaline solution is conveniently a solution of an alkali metal hydroxide or bicarbonate, e.g. sodium hydroxide or sodium bicarbonate, although other alkalis (e.g. aqueous ammonium hydroxide) can also be used. It will be understood that the treatment conditions (and particularly the pH) are dependent on the desired molecular weight range for the resulting product.
However, appropriate conditions can readily be determined in any particular case by routine experiment. By way of example, oxidized regenerated cellulose may be hydrolyzed in 1M to 8M sodium hydroxide at a temperature of from OOC to 500C for 5 to 120 minutes to yield oligosaccharides in the molecular weight range 1000 to 20000 daltons, or with 0.01M to 1M sodium bicarbonate at 0 0C to 500C for 10 hours to 10 days to yield oligosaccharides in the molecular weight range 7000 to 50000.
The hydrolytic reaction can be stopped by the addition of an acid, such as a mineral acid, until the solution is approximately neutral. Concentrated hydrochloric acid can conveniently be used.
The invention is further described by the followingExamples.
ExamPle 1A solution of ORC was prepared by dissolving Surgical" fabric at a concentration of 20mg/ml in 6M sodium hydroxide.
The solution was incubated at 370C for 45 minutes after which the reaction was stopped by adding 6M HCl until precipitation occurred and the pH changed from alkaline to pH7 or less. The precipitate was allowed to settle overnight, and then the excess liquid was removed. The precipitate was dialysed against water in tubing with a 1000 molecular weight cut off, then freeze dried to product a powder.
The molecular size of the oligosaccharide, determined by gel electrophoresis and by high performance liquid chromatography, showed a range extending from approximately 1000 to 15000 daltons.
Example 2A solution of ORC was prepared by dissolving SurgicelN fabric at a concentration of 10mg/ml in 0.lM sodium bicarbonate. The solution was incubated at 370C for a few days (2-3) until all the ORC has dissolved. The reaction was stopped by adding 6M HCl until precipitation occurred and the pH changed from alkaline to pH7 or less. The precipitate was allowed to settle overnight and then the excess liquid removed. The precipitate was dialysed against water in tubing with a 1000 molecular weight cut off, then freeze dried to product a powder.
The molecular size, determined as described above, showed a range from approximately 1000 to 30000 daltons.
Example 3Oxidized carboxymethyl cellulose sponge was prepared as follows:Into 500 grams of water is added with stirring 7.5 grams of carboxymethylcellulose (CMC) from AqualonCorporation. When the polymer is dissolved the solution is allowed to deaerate overnight to remove trapped air bubbles.
The solution is poured into trays 3x4xi inch, and freeze dried for 24 hours in a lyophilizer. Soft, white, water soluble CMC sponges are obtained from this procedure.
The oxidation of the CMC sponges is accomplished by placing 5.8 grams of dry sponges into a resin kettle to which is attached a small flask containing 8 grams of nitrogen tetroxide. The nitrogen tetroxide is allowed to evaporate from the small flask into the resin kettle and envelope the CMC sponges in an atmosphere of gas. The sponges are kept in the resin kettle for 48 hours after which time the gas is evacuated to caustic trap and the sponges are removed and placed in 500ml of water. The oxidized CMC sponges are not soluble in water. They are washed with water for 15 minutes then placed in fresh water for another wash. This washing of the oxidized sponges is repeated until the pH of the wash water is above 3. The white oxidized carboxymethylcellulose sponges are dried by placing them in 100% isopropyl alcohol for 15 minutes. This is repeated for a total of 2 washes then the sponges are allowed to air dry. The oxidized CMC sponges are soft and conformable and will absorb 14 times their weight in isotonic saline. They are soluble in 0.5N sodium hydroxide and are characterized by their carboxylic acid content which is found by titration to be 26.3%.
A solution of the oxidized carboxymethyl cellulose was prepared by dissolving the sponge material at a concentration of lOmg/ml in 0.lM ammonium hydroxide. The solution was incubated at 370C for 2 hours, and the reaction was then stopped by the addition of 6M HCl until precipitation occurred. The precipitate was collected and dialysed extensively against distilled water in tubing with a 1000 dalton molecular weight cut off, then freeze dried to produce a powder.
The molecular weight was determined by gel electrophoresis and found to be 1000 and 30000 daltons.
Example 4Methyl cellulose was oxidized by a procedure analogous to that described in Example 3, and a solution was prepared by dissolving the oxidized material at a concentration of 20mg/ml in 6M sodium hydroxide and incubating at 37 0C for 45 minutes. The solution was centrifuged to remove any undissolved material, and the oligosaccharides were precipitated out of solution by the addition of 6M HCl. The precipitate was collected and dialysed extensively against distilled water in tubing with a 1000 dalton molecular weight cut off.
The molecular weight was determined by gel electrophoresis and found to be between 1000 and 5000 daltons.
Example 5A phenyl boronic acid (PBA) solid phase extraction column (Bond Elut, Varian Associates), containing 100mg of sorbent material with a 10ml reservoir, was activated using 10ml of methanol to wet the column, followed by 10ml 0.1M acetic acid to equilibrate the column at the correct pH.
ORC solution was prepared by dissolving Ig of Interceded" material in 100ml EM sodium hydroxide solution.
After the Interceded material had fully dissolved, the solution was acidified to pH 3.0 and any precipitate was removed by centrifugation. The supernatant was taken, and 2ml was passed through the activated PBA column. The column was then washed with 2ml 0.1M acetic acid and 4x2ml portions of distilled water to remove any salt or other endogenous material. The ORC oligosaccharides were eluted from the column using 2x2ml portions of 0.1M ammonium hydroxide. the portions were pooled, frozen and lyophilised to produce a powder. After separation of the oxidized oligosaccharides by ion-exchange chromatography, mass spectrographic analysis shows them to have a molecular weight in the range 600 to 1200 daltons.
Example 6A collagen/ORC oligosaccharide sponge was prepared in the following way. Limed collagen fibres (0.8g) were slurried in 160ml 0.01 HCl (pH3.0), and 0.16g of ORC oligosaccharide, prepared as in Example 2 (molecular weight 1000-150000Da), was added. The mixture was homogenised for 15 seconds, HMDI was added (10% w/w of collagen) and the slurry was homogenised for a further 2 x 15 seconds. The slurry was degassed, poured into two 9cm diameter petri dishes, frozen and freeze dried using a heat ramp running from -30 to 700C over 72 hours.
The collagen/ORC oligosaccharide sponge was then tested for its ability to bind platelet-derived growth factor (PDGF). For comparative purposes, Interceded" fabric and a simple collagen sponge (prepared as described above, but without the addition of ORC oligosaccharide) were also tested. In each case, a small section of test material (approximately 1cam2 squares of Interceded" fabric, and approximately lcm x 0.5cm x 0.4cm sections of sponge) were weighed and soaked in 100mM sodium phosphate dibasic buffer containing 150mM sodium chloride (total volume lml) for at least one hour at room temperature. Samples were then incubated with 2% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 2 hours at room temperature. 25ng of PDGF was then added to each sample in 25041 of PBS containing 2% BSA, and samples were then incubated for a further hour at 370C.
Each sample was then washed three times with 25041 PBS followed by increasing concentrations of sodium chloride.
Finally, each sample was washed with 4.OM urea. ELISA analyses of the original PDGF preparation and the various washings from the sample materials provided the following results: TABLE I: BINDING OF PDGF-ABSAMPLE COLLAGEN COLL/ORC INTERCEEDOriginal 100% 100% 100%Unbound 20.6% 22.9% 15.4%PBS wash 1.8% 11.1% 7.5% 0.3M NaCl 4.50% 12.3% 1.9% 0.5M NaCl 22.0% 22.2% 7.7% 1.OM NaCl 11.9% 15.2% 11.2% 2.0M NaCl 3.0% 5.1% 7.8% 3.OM NaCl 0% 4.3% 3.4% 4.OM urea 0% 4.0% 9.7%Recovered 63.8% 97.1% 64.6% The results show that the three test materials all bind similar quantities of PDGF, but PDGF can be recovered in highest yield from the collagen/ORC oligosaccharide sponge.
The binding characteristics are also uniquely different for the collagen/ORC oligosaccharide materials compared with the individual comparison materials. These observations indicate the complex has unique binding of PDGF which may be utilized appropriately for both exogenous binding and endogenous binding and release of growth factor.

Claims (19)

GB9613683A1996-06-281996-06-28Oxidized oligosaccharides and pharmaceutical compositionsRevokedGB2314840B (en)

Priority Applications (17)

Application NumberPriority DateFiling DateTitle
GB9613683AGB2314840B (en)1996-06-281996-06-28Oxidized oligosaccharides and pharmaceutical compositions
AT97928373TATE195742T1 (en)1996-06-281997-06-27 OXIDATED OLIGOSACCHARIDES
HU9903404AHUP9903404A3 (en)1996-06-281997-06-27Oxidized oligosaccharides
PCT/GB1997/001726WO1998000446A1 (en)1996-06-281997-06-27Oxidized oligosaccharides
PT97928373TPT907664E (en)1996-06-281997-06-27 OLIGOSACARIDEOS OXIDADOS
KR1019980710708AKR20000022286A (en)1996-06-281997-06-27Oxidized oligosaccharides
EP97928373AEP0907664B1 (en)1996-06-281997-06-27Oxidized oligosaccharides
BR9710003-0ABR9710003A (en)1996-06-281997-06-27 Oxidized oligosaccharides
PL97330825APL189194B1 (en)1996-06-281997-06-27Oxidised oligosaccharides
JP50391398AJP4302187B2 (en)1996-06-281997-06-27 Oxidized oligosaccharide
CZ19984274ACZ294839B6 (en)1996-06-281997-06-27Pharmaceutical composition for topical, oral or parenteral administration, its use and process for preparing active substance thereof
AU32693/97AAU725296B2 (en)1996-06-281997-06-27Oxidized oligosaccharides
DE69702911TDE69702911T2 (en)1996-06-281997-06-27 OXYDATED OLIGOSACCHARID
ES97928373TES2148991T3 (en)1996-06-281997-06-27 OXIDIZED OLIGOSACCHARIDES.
CA002258849ACA2258849C (en)1996-06-281997-06-27Oxidized oligosaccharides
GR20000402542TGR3034853T3 (en)1996-06-282000-11-15Oxidized oligosaccharides
JP2008314228AJP5208707B2 (en)1996-06-282008-12-10 Method for producing oxidized cellulose

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
GB9613683AGB2314840B (en)1996-06-281996-06-28Oxidized oligosaccharides and pharmaceutical compositions

Publications (3)

Publication NumberPublication Date
GB9613683D0 GB9613683D0 (en)1996-08-28
GB2314840Atrue GB2314840A (en)1998-01-14
GB2314840B GB2314840B (en)2000-09-06

Family

ID=10796095

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GB9613683ARevokedGB2314840B (en)1996-06-281996-06-28Oxidized oligosaccharides and pharmaceutical compositions

Country Status (16)

CountryLink
EP (1)EP0907664B1 (en)
JP (2)JP4302187B2 (en)
KR (1)KR20000022286A (en)
AT (1)ATE195742T1 (en)
AU (1)AU725296B2 (en)
BR (1)BR9710003A (en)
CA (1)CA2258849C (en)
CZ (1)CZ294839B6 (en)
DE (1)DE69702911T2 (en)
ES (1)ES2148991T3 (en)
GB (1)GB2314840B (en)
GR (1)GR3034853T3 (en)
HU (1)HUP9903404A3 (en)
PL (1)PL189194B1 (en)
PT (1)PT907664E (en)
WO (1)WO1998000446A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2000033893A1 (en)*1998-12-072000-06-15Johnson & Johnson Medical LimitedSterile complex of therapeutic peptide bond to a polysaccharide
GB2354708A (en)*1999-10-012001-04-04Johnson & Johnson Medical LtdCompositions for wound contracture
EP1153618A1 (en)*2000-05-122001-11-14Johnson & Johnson Medical Ltd.Use of oxidized cellulose as free radical scavenger
EP1153620A3 (en)*2000-05-122003-05-28Johnson & Johnson Medical Ltd.Solid compositions exhibiting selective binding to dissolved iron
EP1323436A1 (en)*2001-12-262003-07-02Amitie Co., Ltd.Anti-adhesion barrier comprising carboxymethylcellulose and gellan gum
EP1325753A3 (en)*2001-12-212003-10-01Ethicon, Inc.Bio-compatible means for controlled drug delivery to tissue and method of use
WO2004024197A1 (en)*2002-09-112004-03-25Johnson & Johnson Medical LimitedWound dressing materials comprising complexes of anionic polysaccharides with silver
EP1462122A1 (en)*2003-03-252004-09-29Ethicon, Inc.Hemostatic wound dressings and methods of making same
US6911053B1 (en)1999-01-052005-06-28Unilever Home & Personal Care Usa, A Division Of Conopco, Inc.Treatment for fabrics
WO2005054297A3 (en)*2003-11-282005-10-06Eastman Chem CoCellulose interpolymers and method of oxidation
US7019191B2 (en)2003-03-252006-03-28Ethicon, Inc.Hemostatic wound dressings and methods of making same
US7252837B2 (en)2002-06-282007-08-07Ethicon, Inc.Hemostatic wound dressing and method of making same
US7262181B2 (en)*2001-04-302007-08-28Beijing Textile Research InstituteWater soluble cellulose etherified derivatives styptic materials
US7666803B2 (en)2004-10-202010-02-23Ethicon, Inc.Reinforced absorbable multilayered fabric for use in medical devices
WO2009039238A3 (en)*2007-09-192010-02-25Ut-Battelle, LlcBioresorbable calcium-deficient hydroxyapatite hydrogel composite
DE102011007528A1 (en)*2011-04-152012-10-18Aesculap Aktiengesellschaft Thixotropic composition, in particular for post-surgical adhesion prophylaxis
US8709463B2 (en)2003-06-252014-04-29Ethicon, Inc.Hemostatic devices and methods of making same
US9439997B2 (en)2004-10-202016-09-13Ethicon, Inc.Reinforced absorbable multilayered hemostatis wound dressing

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7112320B1 (en)1995-06-072006-09-26Andre BeaulieuSolid wound healing formulations containing fibronectin
US6309454B1 (en)2000-05-122001-10-30Johnson & Johnson Medical LimitedFreeze-dried composite materials and processes for the production thereof
US20040101547A1 (en)*2002-11-262004-05-27Pendharkar Sanyog ManoharWound dressing containing aldehyde-modified regenerated polysaccharide
GB2392913B (en)*2002-09-112007-04-04Johnson & Johnson Medical LtdWound dressings comprising complexes of oxidised celluloses with silver
GB2393120A (en)*2002-09-182004-03-24Johnson & Johnson Medical LtdCompositions for wound treatment
US8685943B2 (en)2003-03-122014-04-01Hill's Pet Nutrition, Inc.Methods for reducing diarrhea in a companion animal
DE10319808A1 (en)*2003-04-282004-11-18Friedrich-Schiller-Universität JenaUse of carboxy-substituted polysaccharides, such as carboxy cellulose or carboxymethyl cellulose, for stimulating cell proliferation e.g. to treat wounds
GB2408206B (en)2003-11-182007-11-28Johnson & Johnson Medical LtdAntioxidant and antimicrobial wound dressing materials
WO2006034293A2 (en)*2004-09-172006-03-30Dixon David MWound care dressing and method using same
US9358318B2 (en)2004-10-202016-06-07Ethicon, Inc.Method of making a reinforced absorbable multilayered hemostatic wound dressing
EP1919959B1 (en)2005-09-022016-10-26Hemcon Medical Technologies (IP) LimitedA method for preparing polyanhydroglucuronic acid and/or salts thereof
JP4975996B2 (en)*2005-09-302012-07-11東邦化学工業株式会社 Cation-modified pectin and cosmetic composition containing the substance
GB2444232A (en)2006-11-302008-06-04Ethicon IncWound dressing compositions comprising cell lysates
US9376648B2 (en)2008-04-072016-06-28The Procter & Gamble CompanyFoam manipulation compositions containing fine particles
JP2010284216A (en)*2009-06-092010-12-24Hogi Medical:Kk Carboxymethylcellulose structure and method for producing the same
JP5818055B2 (en)*2010-03-172015-11-18静岡県公立大学法人 Triacetyl cellulose block copolymer, its intermediate, filler, and surfactant
EP2692739B1 (en)*2011-03-302019-07-03Nippon Paper Industries Co., Ltd.Method for producing cellulose nanofibers
WO2012171725A2 (en)*2011-06-162012-12-20Unilever PlcAqueous gels
CN104945448B (en)*2015-05-222018-06-19上海绿谷制药有限公司A kind of oxidized form β -1,4- oligoglucoses aldehydic acid and its preparation method and application
CN107849154A (en)*2016-06-022018-03-27郡是株式会社Medical fibre structure and medical laminated material
KR102294257B1 (en)*2019-04-302021-08-26한양대학교 에리카산학협력단Biocellulose-peptide composite and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB188992A (en)*1921-01-031922-11-23Albert ReychlerA method of preparing solutions of starch
EP0268885A2 (en)*1986-11-211988-06-01Ajorca S.A.A process for controlled depolymerization of polysaccharides
JPH06279504A (en)*1993-03-261994-10-04Lion CorpProduction of sequestering oligomer compound and detergent composition containing the same
US5414079A (en)*1993-08-031995-05-09Biocontrol IncorporatedOxidized cellulose
EP0676415A2 (en)*1994-04-051995-10-11Hoechst AktiengesellschaftProcess for producing low molecular weight polysaccharide ethers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2517772A (en)*1945-05-111950-08-08Parke Davis & CoNeutralized oxidized cellulose products
US3598622A (en)*1969-02-191971-08-10Cpc International IncAlkali treated starch compositions
CA2033046C (en)*1990-01-121999-08-03Lowell SafersteinProcess for preparing a neutralized oxidized cellulose product and its method of use
CN1035803C (en)*1990-07-241997-09-10中国化工进出口总公司Soluble hemostyptic fabric
CA2071137A1 (en)*1991-07-101993-01-11Clarence C. LeeComposition and method for revitalizing scar tissue

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB188992A (en)*1921-01-031922-11-23Albert ReychlerA method of preparing solutions of starch
EP0268885A2 (en)*1986-11-211988-06-01Ajorca S.A.A process for controlled depolymerization of polysaccharides
JPH06279504A (en)*1993-03-261994-10-04Lion CorpProduction of sequestering oligomer compound and detergent composition containing the same
US5414079A (en)*1993-08-031995-05-09Biocontrol IncorporatedOxidized cellulose
EP0676415A2 (en)*1994-04-051995-10-11Hoechst AktiengesellschaftProcess for producing low molecular weight polysaccharide ethers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WPI Abstract Accession Number 94-354775/44 & JP 06 279 504 A*

Cited By (30)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2000033893A1 (en)*1998-12-072000-06-15Johnson & Johnson Medical LimitedSterile complex of therapeutic peptide bond to a polysaccharide
US6911053B1 (en)1999-01-052005-06-28Unilever Home & Personal Care Usa, A Division Of Conopco, Inc.Treatment for fabrics
GB2354708A (en)*1999-10-012001-04-04Johnson & Johnson Medical LtdCompositions for wound contracture
WO2001024841A1 (en)*1999-10-012001-04-12Johnson & Johnson Medical LimitedCompositions for the treatment of wound contracture
GB2354708B (en)*1999-10-012004-06-02Johnson & Johnson Medical LtdCompositions for the treatment of wound contracture
EP1153618A1 (en)*2000-05-122001-11-14Johnson & Johnson Medical Ltd.Use of oxidized cellulose as free radical scavenger
EP1153620A3 (en)*2000-05-122003-05-28Johnson & Johnson Medical Ltd.Solid compositions exhibiting selective binding to dissolved iron
US7262181B2 (en)*2001-04-302007-08-28Beijing Textile Research InstituteWater soluble cellulose etherified derivatives styptic materials
EP1325753A3 (en)*2001-12-212003-10-01Ethicon, Inc.Bio-compatible means for controlled drug delivery to tissue and method of use
EP1323436A1 (en)*2001-12-262003-07-02Amitie Co., Ltd.Anti-adhesion barrier comprising carboxymethylcellulose and gellan gum
US7252837B2 (en)2002-06-282007-08-07Ethicon, Inc.Hemostatic wound dressing and method of making same
US7279177B2 (en)2002-06-282007-10-09Ethicon, Inc.Hemostatic wound dressings and methods of making same
WO2004024197A1 (en)*2002-09-112004-03-25Johnson & Johnson Medical LimitedWound dressing materials comprising complexes of anionic polysaccharides with silver
US8461410B2 (en)2002-09-112013-06-11Ethicon, Inc.Wound dressing materials comprising complexes of anionic polysaccharides with silver
US7019191B2 (en)2003-03-252006-03-28Ethicon, Inc.Hemostatic wound dressings and methods of making same
EP1462122A1 (en)*2003-03-252004-09-29Ethicon, Inc.Hemostatic wound dressings and methods of making same
US8709463B2 (en)2003-06-252014-04-29Ethicon, Inc.Hemostatic devices and methods of making same
US9040683B2 (en)2003-11-282015-05-26Eastman Chemical CompanyCellulose interpolymers and method of oxidation
US7879994B2 (en)2003-11-282011-02-01Eastman Chemical CompanyCellulose interpolymers and method of oxidation
US8816066B2 (en)2003-11-282014-08-26Eastman Chemical CompanyCellulose interpolymers and methods of oxidation
US9040684B2 (en)2003-11-282015-05-26Eastman Chemical CompanyCellulose interpolymers and method of oxidation
WO2005054297A3 (en)*2003-11-282005-10-06Eastman Chem CoCellulose interpolymers and method of oxidation
US9040685B2 (en)2003-11-282015-05-26Eastman Chemical CompanyCellulose interpolymers and method of oxidation
US9150665B2 (en)2003-11-282015-10-06Eastman Chemical CompanyCellulose interpolymers and method of oxidation
US9243072B2 (en)2003-11-282016-01-26Eastman Chemical CompanyCellulose interpolymers and method of oxidation
US7749204B2 (en)2004-10-202010-07-06Ethicon, Inc.Reinforced absorbable multilayered fabric for use in tissue repair and regeneration
US7666803B2 (en)2004-10-202010-02-23Ethicon, Inc.Reinforced absorbable multilayered fabric for use in medical devices
US9439997B2 (en)2004-10-202016-09-13Ethicon, Inc.Reinforced absorbable multilayered hemostatis wound dressing
WO2009039238A3 (en)*2007-09-192010-02-25Ut-Battelle, LlcBioresorbable calcium-deficient hydroxyapatite hydrogel composite
DE102011007528A1 (en)*2011-04-152012-10-18Aesculap Aktiengesellschaft Thixotropic composition, in particular for post-surgical adhesion prophylaxis

Also Published As

Publication numberPublication date
WO1998000446A1 (en)1998-01-08
PL330825A1 (en)1999-06-07
CZ294839B6 (en)2005-03-16
GR3034853T3 (en)2001-02-28
DE69702911T2 (en)2001-02-22
ATE195742T1 (en)2000-09-15
HUP9903404A2 (en)2000-03-28
AU3269397A (en)1998-01-21
CZ427498A3 (en)1999-05-12
KR20000022286A (en)2000-04-25
HUP9903404A3 (en)2001-03-28
BR9710003A (en)2000-01-11
EP0907664B1 (en)2000-08-23
JP4302187B2 (en)2009-07-22
AU725296B2 (en)2000-10-12
ES2148991T3 (en)2000-10-16
EP0907664A1 (en)1999-04-14
JP2000514110A (en)2000-10-24
PL189194B1 (en)2005-07-29
DE69702911D1 (en)2000-09-28
JP2009102645A (en)2009-05-14
GB2314840B (en)2000-09-06
CA2258849C (en)2008-01-22
CA2258849A1 (en)1998-01-08
PT907664E (en)2000-12-29
GB9613683D0 (en)1996-08-28
JP5208707B2 (en)2013-06-12

Similar Documents

PublicationPublication DateTitle
AU725296B2 (en)Oxidized oligosaccharides
AU737809B2 (en)Use of oxidized cellulose and complexes thereof for chronic wound healing
JP3337472B2 (en) Wound healing agent
JP3819567B2 (en) Method for producing polysaccharide sponge
US9808553B2 (en)Haemostatic wound dressing
JPS6147413A (en) Active compound depot
Debele et al.Polysaccharide and protein-based functional wound dressing materials and applications
JP3404557B2 (en) Crosslinked hyaluronic acid and composites thereof
NZ512994A (en)Process for cross-linking hyaluronic acid to different polymers (other than hyaluronic acid)
JPH06343684A (en)Imbibing wound bandage material
EP1147148B1 (en)Dextran-maleic acid monoesters and hydrogels based thereon
Nikolic et al.TEMPO-oxidized cotton as a substrate for trypsin immobilization: impact of functional groups on proteolytic activity and stability
JP2000116765A (en) Anti-adhesion material
JPS6087219A (en) active substance depot
Varguez-Catzim et al.Tailoring membrane technology with galactomannan for enhanced biocompatibility and antibacterial action
JP2004041586A (en) Biocompatible material and method for producing the same
RU2833410C1 (en)Haemostatic agent
Yamazaki et al.Chitosan derivatives for bioadhesive/hemostatic application: chemical and biological aspects
WO2008015475A1 (en)Gels for use in wound management

Legal Events

DateCodeTitleDescription
773KPatent revoked under sect. 73(2)/1977

[8]ページ先頭

©2009-2025 Movatter.jp